Investigators addressed challenges associated with the biology, diagnosis, and current state of treatment for patients with NPM1-mutated AML.
This approach requires a team-coordinated effort by investigators, patients, and caregivers, as well as genomic and cytogenetic laboratories.
Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.
Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
A phase 1b trial found ivosidenib with azacitidine well-tolerated in patients with AML who are ineligible for intensive chemotherapy.
Patients with Philadelphia chromosome-positive ALL were treated with dasatinib and blinatumomab during induction and consolidation therapy — without chemotherapy.
Among patients with AML, maintenance therapy with rhG-CSF plus decitabine led to fewer relapses compared with patients who received no treatment after HSCT.
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
Among patients with acute myeloid leukemia, minimal residual disease-negativity may be linked to improved survival rates.
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Researchers evaluated and validated the effectiveness of a 4-factor prognostic model among patients with CLL treated with ibrutinib.
Addition of midostaurin, a first-generation FLT3 inhibitor, to frontline induction therapy is currently a standard approach to the treatment of FLT3-mutated AML.
The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.
The full approval was based on efficacy and safety data from the phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies.
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
Patients with relapsed/refractory AML who do not respond to venetoclax-based salvage therapy may have a response to intensified chemotherapy.
CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.
Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Risk factors include male sex, older age at diagnosis, White race.
Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.
Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.
Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Patients with newly diagnosed AML who are ineligible for intensive chemotherapy may benefit from a 10-day course of decitabine with venetoclax.
Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.
Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.
Race and ethnicity was a factor in risk for pancreatitis among children with ALL, as was age and presence of obesity and hyperglycemia.
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
Investigators aimed to determine the prognostic value of WT1 expression among patients with AML who were in earlier stages of treatment.
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
Even after treatment with hypomethylating agents, older patients with AML still lack positive prognoses but azacitidine with venetoclax shows promise.
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy.
Researchers assessed the efficacy and safety of sorafenib maintenance among patients with FLT3-ITD AML who underwent allogeneic HSCT.
These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.
Selinexor yields responses in patients with MDS or oligoblastic AML refractory to hypomethylating agents, with manageable adverse events.
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.